BlueBird Fails to Axe Patents in Dispute Over $2 Million Drugs – Bloomberg Law

A US Patent and Trademark Office administrative tribunal quashed bluebird bio Inc.’s efforts to cancel two patents its multi-million dollar drugs LentiGlobin and Zynteglo are accused of infringing.

Sloan Kettering Institute for Cancer Research’s US Patent Nos. 7,541,179 and 8,058,061 covering blood disorder treatments aren’t obvious or anticipated by prior inventions, the Patent Trial and Appeal Board ruled in two decisions issued Monday. Errant Gene Therapeutics, which claims rights to Sloan Kettering’s patents, sued bluebird in 2021 for infringement in the US District Court for the District of Delaware where the case is ongoing.